SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling

Oncogene

Volumn 28, Issue 34, 2009, Pages 3069-3080

  Haan, S ^a   Wuller S ^b   Kaczor, J ^a   Rolvering, C ^a   Nocker T ^b   Behrmann, I ^a   Haan, C ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Janus kinases; Myeloproliferative disorders; Proteasomal degradation; SOCS

Indexed keywords

CYTOKINE; DOXYCYCLINE; JANUS KINASE 2; MUTANT PROTEIN; PROTEASOME; SUPPRESSOR OF CYTOKINE SIGNALING;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLELE; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; DISEASE ASSOCIATION; DOWN REGULATION; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; MUTANT; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UBIQUITINATION; WILD TYPE;

CELL LINE, TUMOR; CYTOKINES; DOWN-REGULATION; HUMANS; JANUS KINASE 2; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 69449087032     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.155     Document Type: Article

References (51)

1. Andrieux JL, Demory JL. (2005). Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 4: 224-229.
2. Bacher U, Haferlach T, Schoch C. (2005). Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. Cancer Genet Cytogenet 160: 179-183. (Pubitemid 40910055)
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061. (Pubitemid 40386783)
4. Behrmann I, Smyczek T, Heinrich PC, Schmitz-Van de Leur H, Komyod W, Giese B et al. (2004). Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. J Biol Chem 279: 35486-35493. (Pubitemid 39100548)
5. Bock O, Busche G, Koop C, Schroter S, Buhr T, Kreipe H. (2006). Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn 8: 170-177. (Pubitemid 43811239)
6. Bock O, Hussein K, Brakensiek K, Buhr T, Schlue J, Wiese B et al. (2007). The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders. Leuk Res 31: 799-803. (Pubitemid 46855894)
7. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L et al. (2006). Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66: 11156-11165. (Pubitemid 46009942)
8. Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, Cerri M et al. (2008). Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 141: 504-511. (Pubitemid 351550557)
9. De Sepulveda P, Ilangumaran S, Rottapel R. (2000). Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem 275: 14005-14008. (Pubitemid 30339671)
10. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K. (2004). Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 77: 233-240. (Pubitemid 39430701)
11. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K et al. (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924. (Pubitemid 27289595)
12. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. (2001). Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 21: 3547-3557. (Pubitemid 32381790)
13. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. (2003). SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101: 2784-2788. (Pubitemid 36857644)
14. Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V et al. (2006). Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 108: 1551-1554. (Pubitemid 44316120)
15. Grandage VL, Everington T, Linch DC, Khwaja A. (2006). Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 135: 303-316. (Pubitemid 44484837)
16. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. (2007). The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109: 4924-4929. (Pubitemid 46827790)
17. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148. (Pubitemid 40663494)
18. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M et al. (2001). The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 276: 12530-12538. (Pubitemid 37385161)
19. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. (2005a). A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790. (Pubitemid 40570926)
20. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A et al. (2005b). Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 106: 3374-3376. (Pubitemid 41609168)
21. Kratz CP, Boll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M. (2006). Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20: 381-383. (Pubitemid 43148689)
22. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. (2006). JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652-1660. (Pubitemid 44316134)
23. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397. (Pubitemid 40544655)
24. Lu X, Huang LJ, Lodish HF. (2008). Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 283: 5258-5266.
25. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. (2005). Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102: 18962-18967. (Pubitemid 43049549)
26. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF et al. (2005). Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105: 2535-2542. (Pubitemid 40387056)
27. Melzner I, Weniger MA, Bucur AJ, Bruderlein S, Dorsch K, Hasel C et al. (2006). Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 118: 1941-1944.
28. Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S et al. (2006). JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108: 2770-2779. (Pubitemid 44777015)
29. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A et al. (1997). Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929. (Pubitemid 27289596)
30. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. (2006). JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20: 471-476. (Pubitemid 43291746)
31. Reilly JT. (2005). Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia. Semin Oncol 32: 359-364. (Pubitemid 41073748)
32. Roder S, Steimle C, Meinhardt G, Pahl HL. (2001). STAT3 is constitutively active in some patients with polycythemia rubra vera. Exp Hematol 29: 694-702. (Pubitemid 32500370)
33. Rui L, Yuan M, Frantz D, Shoelson S, White MF. (2002). SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277: 42394-42398. (Pubitemid 35257562)
34. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. (2000). CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347. (Pubitemid 32043805)
35. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I et al. (1999). Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4: 339-351. (Pubitemid 29359449)
36. Schulein R, Hermosilla R, Oksche A, Dehe M, Wiesner B, Krause G et al. (1998). A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. Mol Pharmacol 54: 525-535. (Pubitemid 28442945)
37. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. (2007). JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468. (Pubitemid 46193073)
38. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al. (1997). A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921.
39. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al. (2006). The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106: 631-635. (Pubitemid 43157627)
40. Teofili L, Martini M, Cenci T, Guidi F, Torti L, Giona F et al. (2008). Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 123: 1586-1592.
41. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. (2008). Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940.
42. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. (2002). Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22: 3316-3326. (Pubitemid 34453973)
43. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al. (2007). Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110: 840-846. (Pubitemid 47267419)
44. Vuong BQ, Arenzana TL, Showalter BM, Losman J, Chen XP, Mostecki J et al. (2004). SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome. Mol Cell Biol 24: 9092-9101. (Pubitemid 39313913)
45. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al. (2006). Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 281: 18177-18183. (Pubitemid 44035617)
46. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. (2006). Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274-4281. (Pubitemid 43801351)
47. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T et al. (1999). The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18: 1309-1320. (Pubitemid 29110315)
48. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE et al. (2001). SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29-35. (Pubitemid 32405812)
49. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG et al. (1995). A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 14: 2816-2826.
50. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S et al. (2006). Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1: e18.
51. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. (2005). Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792. (Pubitemid 40853184)